The DOI matches its Crossref record.
Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group
Open accessAbstract
Purpose: To estimate the antitumor activity and toxicity of irinotecan alone and in combination with vincristine when administered as window therapy and in combination with standard chemotherapy in pediatric patients with newly diagnosed metastatic rhabdomyosarcoma. Patients and Methods: Nineteen patients younger than age 21 years with newly diagnosed metastatic rhabdomyosarcoma or undifferentiated sarcoma received window therapy with two cycles of irinotecan (20 mg/m 2 daily for 5 days, repeated for 2 weeks) and 50 patients received window therapy with vincristine 1.5 mg/m 2 (weeks 0, 1, 3, and 4) and two cycles of irinotecan (20 mg/m 2 daily for 5 days, repeated for 2 weeks). Patients who achieved a partial response (PR) or complete response (CR) received these agents alternating with vincristine (V; 1.5/mg/m 2), dactinomycin (A; 1.5 mg/m 2), and cyclophosphamide (C; 2.2 g/m 2) during weeks 6 through 41. Nonresponders were treated with VAC alone. Radiotherapy was administered to sites of disease at weeks 15 to 21. Results: The window response rate (PR/CR) for patients who received irinotecan was 42% (95% CI, 38% to 80%) but the high progressive disease (PD) rate of 32% (95% CI, 11% to 52%) prompted closure of the trial. The window CR/PR rate for patients who received vincristine and irinotecan was 70% (95% CI, 57% to 83%), and the PD rate was only 8%. GI toxicities (abdominal pain, diarrhea, dehydration) were the most common adverse effects associated with the administration of irinotecan. Conclusion: The combination of vincristine and irinotecan is highly active in metastatic rhabdomyosarcoma. The different mechanism of action and nonoverlapping toxicity profile with VAC makes this combination an attractive candidate for further testing in intermediate risk patients with rhabdomyosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Skapek, S. X., Ferrari, A., Gupta, A. A., Lupo, P. J., Butler, E., Shipley, J., Barr, F. G., & Hawkins, D. S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0051-2 · Cited by 875
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0025 · Cited by 736
Self-citationOberlin, O., Rey, A., Lyden, E., Bisogno, G., Stevens, M. C. G., Meyer, W. H., Carli, M., & Anderson, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7207 · Cited by 484
Self-citationMalempati, S., & Hawkins, D. S. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24118 · Cited by 422
Arndt, C. A. S., Stoner, J. A., Hawkins, D. S., Rodeberg, D. A., Hayes-Jordan, A. A., Paidas, C. N., Parham, D. M., Teot, L. A., Wharam, M. D., Breneman, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3768 · Cited by 380
Self-citationSoft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Conrad, E. U., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0078 · Cited by 297
Self-citationNorris, R. E., Shusterman, S., Gore, L., Muscal, J. A., Macy, M. E., Fox, E., Berkowitz, N., Buchbinder, A., & Bagatell, R. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25105 · Cited by 38
Metadata
- Authors
- Pappo, A. S., Lyden, E., Breitfeld, P., Donaldson, S. S., Wiener, E., Parham, D., Crews, K. R., Houghton, P., & Meyer, W. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-02-01
- Volume
- 25
- Issue
- 4
- Pages
- 362-369
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112772060
- Cited by
- 201
- References
- 0
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.